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 Severe fever with thrombocytopenia syndrome phlebovirus (SFTSV) listed in the World 45 
Health Organization Prioritized Pathogens is an emerging Phlebovirus with a high fatality1-4. Due 46 
to the lack of therapies and vaccines5,6, there is a pressing need to understand SFTSV 47 
pathogenesis. SFSTV nonstructural protein (NSs) has been shown to block type-I interferon 48 
(IFN) induction7-11 and facilitate disease progression12,13. Here, we report that SFTSV NSs 49 
targets the TPL2-ABIN2-p105 complex to induce the expression of IL-10 for viral pathogenesis. 50 
Combination of reverse genetics, TPL2 kinase inhibitor and Tpl2-/- mice showed that NSs 51 
interacted with ABIN2 and promoted TPL2 complex formation and signalling activity, resulting in 52 
the marked upregulation of Il-10 expression. While SFTSV infection of wild-type mice led to 53 
rapid weight loss and death, Tpl2-/- mice or Il-10-/- mice survived an infection. Furthermore, 54 
SFTSV-NSs P102A and SFTSV-NSs K211R that lost the ability to induce TPL2 signalling and IL-55 
10 production showed drastically reduced pathogenesis. Remarkably, the exogenous 56 
administration of recombinant IL-10 effectively rescued the attenuated pathogenic activity of 57 
SFTSV-NSs P102A, resulting in a lethal infection. Our study demonstrates that SFTSV NSs 58 
targets the TPL2 signalling pathway to induce immune suppressive IL-10 cytokine production as 59 
means to dampen the host defense and promote viral pathogenesis. 60 
 61 
62 
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SFTSV contains three segments of negative or ambisense RNA genome designated as 63 
large (L), medium (M), and small (S). The S segment encodes a nucleoprotein (N) and a 64 
nonstructural protein (NSs) via an ambisense coding strategy2. As SFTSV infection has been 65 
demonstrated to lead to the suppression of host antiviral immunity, work has shown that NSs 66 
plays an important role in immune evasion by interacting with type I interferon (IFN) signalling 67 
effectors RIG-I, MAVS, TRIM25, TBK1, and STAT1, leading to their sequestration to virus-68 
induced inclusion bodies (IB), resulting in the inhibition of IFN and NF-κB responses7-11. Similar 69 
to SFTSV NSs, the NSs protein of other phleboviruses including Heartland-, Bhanja-, Granada-, 70 
and Lone Star viruses except for an apathogenic Uukuniemi virus (UUKV) were able to 71 
effectively suppress the activation of the IFN-β (Ifnb1) promoter induced by Sendai virus (SeV) 72 
infection (Supplementary Fig. 1a). Surprisingly, when aligned with the NSs of other pathogenic 73 
phleboviruses, SFTSV NSs exhibited limited homology, except for two conserved sequences 74 
(S97xLRWPxG104 and D282WP284). SFTSV NSs also carries two potential protein-interacting 75 
motifs (P66xxP69 for SH3 interaction and W133xxL136 for LC3 interaction) (Supplementary Fig. 1b). 76 
When NSs mutants carrying changes at these four sequences were examined for IB formation 77 
and IFN signalling suppression, three mutants (NSs-WxxL, NSs-PxxP, and NSs-DWP) formed 78 
cytoplasmic IBs similar to NSs wild-type (WT), whereas a NSs-8A mutant carrying alanine 79 
substitutions of the S97xLRWPxG104 8 amino acids could no longer form IBs (Supplementary 80 
Fig. 2a). NSs-WT and three mutants that retained the ability to form IBs potently suppressed 81 
SeV-induced IFN-β promoter activation, whereas NSs-8A that didn’t form IBs did not 82 
(Supplementary Fig. 2b). Furthermore, a NSs-P102A (PA) mutant carrying an alanine 83 
replacement within the SxLRWPxG sequence neither formed IBs, nor suppressed the 84 
expression and secretion of IFN-β upon SeV infection (Fig. 1ab and Supplementary Fig. 2c, 85 
respectively). These results indicate the direct correlation between the IB formation and the IFN 86 
signaling-inhibition ability of SFTSV NSs. 87 
We next investigated the effects of NSs on host immune gene expression either in 88 
Raw264.7 cells expressing NSs or upon WT or mutant SFTSV infection of Ifnar-/- mice. Using a 89 
reverse genetic system14, we rescued wild-type virus (SFTSV-WT) and NSs-PA mutant virus 90 
(SFTSV-PA) (Supplementary Fig. 2d). While SFTSV-WT produced larger plaques than SFTSV-91 
PA, both viruses had similar replication kinetics in IFN-negative Vero E6 cells (Supplementary 92 
Fig. 2ef). Total RNA isolated from the spleens of mock-, SFTSV-WT- or SFTSV-PA-infected 93 
Ifnar-/- mice or from Raw264.7-vector or Raw264.7-NSs-WT cells with or without 94 
lipopolysaccharide (LPS) stimulation were subjected to NanoString analysis (Supplementary 95 
Fig. 3a and Supplementary Data). SFTSV-WT infection of Ifnar-/- mice not only broadly induced 96 
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immune response genes, but also markedly suppressed IFN-responsible genes compared to 97 
SFTSV-PA infection (Fig. 1cd and Supplementary Fig. 3bc). Remarkably, the majority of 98 
downregulated host genes in SFTSV-WT-infected mouse spleens were B cell-specific genes 99 
(Fig. 1c and Supplementary Fig. 3d), which appeared to be consistent with recent reports15,16. 100 
Interestingly, nine genes (Il-10, PD-L1, Phlpp1, Sele, Socs3, Nos2, Cxcl1, Cxcl13, and Hif1α), 101 
which were comprehensively induced by SFTSV-WT infection in Ifnar-/- mice or by NSs-WT 102 
expression in Raw264.7 cells, but not by SFTSV-PA infection, function in immune suppressive 103 
pathways (Fig. 1e and Supplementary Table. 1). 104 
In particular, IL-10 is an anti-inflammatory cytokine that limits host immune responses to 105 
pathogens to prevent its own damage17 and is induced by many viruses to dampen the host 106 
defense18-20. Real-time quantitative RT-PCR showed that NSs-WT markedly increased Il-10 107 
expression in Raw264.7 cells by ~50 fold under no stimulation, and by ~200 and ~1300 fold 108 
upon SeV infection or LPS stimulation, respectively, whereas NSs-PA induced little or no Il-10 109 
expression under any conditions (Fig. 1f-i). Furthermore, SFTSV-WT infection, but not SFTSV-110 
PA infection, considerably induced Il-10 expression in Raw264.7 cells, mouse bone marrow 111 
derived macrophages (BMDMs), and human whole blood in vitro (Fig. 1j-l). In addition, SFTSV-112 
WT infection led to the increase of Il-10 expression in spleens and livers of Ifnar-/- mice by ~70 113 
and ~200 fold, respectively, whereas SFTSV-PA infection showed little or no increase of Il-10 114 
expression (Fig. 1mn). Finally, we also found highly-elevated levels of IL-10 in blood of SFTSV-115 
infected patients along with IL-6 and TNFα (Fig. 1o and Supplementary Fig. 3e). These findings 116 
collectively indicate that the SFTSV NSs robustly induces Il-10 expression. 117 
Yeast two-hybrid (Y2H) screen found that NSs interacted with A20-binding protein 2 118 
(ABIN2). Co-immunoprecipitation (Co-IP) showed the specific interaction of NSs with 119 
exogenous ABIN2 in HEK293T cells and endogenous ABIN2 in Raw264.7 cells (Fig. 2ab) as 120 
well as the interaction of virally-produced NSs with ABIN2 in SFTSV-infected Raw264.7 cells 121 
(Fig. 2c). Furthermore, NSs specifically bound to ABIN2 but not to ABIN1 and ABIN3 despite 122 
their high homology21 (Fig. 2d). By using truncation mutagenesis, the middle region (148-220) of 123 
NSs was found to be responsible for ABIN2-binding (Supplementary Fig. 4a). Y2H mapping and 124 
Glutathione S-transferase (GST) pull-down assays revealed the ABIN homology domains 125 
(AHDs) of ABIN2 for efficient NSs interaction (Supplementary Fig. 4bc). The single-molecule 126 
pull-down (SiMPull) assay22 also revealed that SFTSV NSs effectively bound to ABIN2 127 
(Supplementary Fig. 4d). Finally, the NSs protein of other phleboviruses showed interaction with 128 
ABIN2 as strongly as the SFTSV NSs (Supplementary Fig. 4e). However, the UUKV NSs 129 
neither bound ABIN2 nor induced Il-10 expression (Supplementary Fig. 4fg). In parallel, UUKV 130 
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infection failed to induce Il-10 expression compared to SFTSV and Heartland virus infection 131 
(Supplementary Fig. 4h). These suggest the strong correlation between NSs-induced Il-10 132 
expression and phlebovirus pathogenesis. 133 
 ABIN2 preferentially forms a ternary complex with TPL2 kinase (tumor progression locus 134 
2) and p105/NF-κB1 that is required to maintain TPL2 stability23. Differential translational 135 
initiation of the Tpl2 mRNA gives rise to two isoforms (p58 and p52)24. Upon LPS stimulation, 136 
p58 TPL2 is preferentially released from p105 relative to p52 TPL2 and released p58 TPL2 137 
initiates downstream signalling and subsequently undergoes rapid degradation24. NSs-WT-138 
expressing Raw264.7 cells showed increased amounts of TPL2 (p58/p52) and the rapid 139 
degradation of p58 TPL2 compared to vector- or NSs-PA-expressing Raw264.7 cells (Fig. 2e). 140 
SiMPull assay also revealed that NSs-WT, but not NSs-PA, increased the TPL2-ABIN2-p105 141 
ternary complex formation (Fig. 2f). As this ternary complex formation governs TPL2 stability 142 
and its signalling activity, expression of the NSs-WT but not the NSs-PA increased TPL2 143 
amounts, ultimately resulting in the enhanced activation of downstream MEK1/2 and ERK1/2 144 
upon LPS stimulation as evidenced by increased reactivity of their activation-dependent 145 
phospho-specific antibodies (Fig. 2e). Thus, SFTSV NSs stabilizes and activates the TPL2 146 
signalling complex through its specific interaction with ABIN2 (Supplementary Fig. 4i). Indeed, 147 
depletion of ABIN2 expression not only abrogated the interaction between NSs-WT and 148 
TPL2/p105 (Supplementary Fig. 5ab), but also led to the reduction of NSs-mediated induction of 149 
Il-10 expression (Supplementary Fig. 5c).  150 
ABIN2 alone formed cytoplasmic punctate structures similar to NSs (Supplementary Fig. 151 
6a). When NSs and ABIN2 were co-expressed, they showed partial co-localization. Surprisingly, 152 
NSs-PA showed much higher ABIN2 binding and co-localization compared to NSs-WT (Fig. 2g 153 
and Supplementary Fig. 6ab). Increasing expression of NSs-PA suppressed NSs-WT activity to 154 
induce TPL2-mediated Il-10 expression, despite its increased ABIN2 binding (Supplementary 155 
Fig. 7ab). Additional mutation analyses identified that the NSs-K211R (KR) mutant, carrying 156 
replacement of the lysine 211 with arginine (Supplementary Fig. 1b), neither bound ABIN2 (Fig. 157 
2g) nor induced Il-10 expression upon LPS stimulation or SeV infection (Fig. 2h and 158 
Supplementary Fig. 7c). While the NSs-WT and NSs-PA interacted with TPL2 and p105 through 159 
ABIN2 binding, the NSs-KR showed no interaction with TPL2 and p105 due to its lack of ABIN2 160 
binding (Supplementary Fig. 7de). Moreover, the P102A and K211R double-mutant (NSs-PK) also 161 
showed the loss of ABIN2 interaction (Supplementary Fig. 7f). Functionally, NSs-KR did not 162 
activate downstream MEK1/2 and ERK1/2 upon LPS stimulation (Supplementary Fig. 7g). 163 
Moreover, SFTSV-KR infection of Raw264.7 cells and mice led to a little or no increase of Il-10 164 
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expression (Fig. 2i  and Supplementary Fig. 7h). On the other hand, NSs-KR interacted with 165 
TBK1 and suppressed SeV-induced IFN-β promoter activation as strongly as NSs-WT, whereas  166 
NSs-PA could not do both (Supplementary Fig. 7ij), suggesting that NSs-mediated regulation of 167 
TPL2 signalling is genetically seperable from its regulation of IFN signalling. 168 
As the TPL2 signalling pathway is important for Il-10 expression in macrophage25, 169 
treatment with a TPL2 inhibitor (CAS1186649-59-1) not only suppressed the basal level of Il-10 170 
expression but also abrogated the NSs-mediated upregulation of Il-10 expression (Fig. 3a). 171 
Consistently, MEK inhibitor, but not c-Raf kinase inhibitor, suppressed the NSs-mediated Il-10 172 
upregulation (Fig. 3b). Moreover, NSs-WT markedly induced Il-10 expression in WT BMDMs, 173 
but not in Tpl2-/- BMDMs. In contrast, NSs-PA did not induce Il-10 expression in either WT or 174 
Tpl2-/- BMDMs (Fig. 3c). Correspondingly, SFTSV-WT infection upregulated Il-10 expression in 175 
WT or Ifnar-/- BMDMs but not in Tpl2-/- BMDMs, whereas SFTSV-PA infection did not upregulate 176 
Il-10 expression under any conditions (Fig. 3d). Treatment with the TPL2 inhibitor also 177 
abrogated Il-10 expression in SFTSV-WT-infected Ifnar-/- BMDMs (Fig. 3e). Finally, Il-10 178 
expression was considerably upregulated in spleens of SFTSV-WT-infected mice compared to 179 
those of SFTSV-WT-infected Tpl2-/- mice where both mice were pretreated with anti-IFNAR1 180 
blocking antibody prior to infection (Fig. 3f). As an activated p58 TPL2 undergoes rapid 181 
degradation24, SFTSV-WT-infected BMDMs showed the reduced p58 TPL2 along with MEK1/2 182 
and ERK1/2 activation compared to mock- or SFTSV-PA-infected BMDMs, resulting in the 183 
marked increase of Il-10 expression (Fig. 3gh). Intriguingly, the TPL2 inhibitor did not affect the 184 
degradation of p58 TPL2, while it detectably reduced MEK1/2 phosphorylation (Fig. 3i), 185 
suggesting that NSs specifically targets the TPL2-ABIN2-p105 complex formation, not the p58 186 
TPL2 degradation. Of note, the TPL2 signalling pathway was not required for SeV- or LPS-187 
induced IFN-β expression, nor for NSs-mediated IFN-β suppression (Supplementary Fig. 8ab). 188 
Moreover, NSs did not affect Tpl2 expression upon several stimulation conditions 189 
(Supplementary Fig. 8cd). These results indicate that SFTSV NSs specifically enhances TPL2 190 
complex formation and its signalling activity, resulting in the upregulation of Il-10 expression. 191 
 While SFTSV-WT and SFTSV-PA replicated in IFN-negative Vero E6 cells at similar 192 
kinetics (Supplementary Fig. 2f), the viral copy numbers of SFTSV-WT were approximately 1.5 193 
logs higher in vitro than those of SFTSV-PA in WT, Tpl2-/-, and Ifnar-/- BMDMs as well as in 194 
human whole blood (Supplementary Fig. 9ab). SFTSV-WT also replicated slightly higher than 195 
SFTSV-PA in the spleens and livers of Ifnar-/- mice (Supplementary Fig. 9c). On the other hand, 196 
treatment with TPL2 inhibitor did not significantly affect SFTSV-WT replication in Ifnar-/- BMDMs 197 
(Supplementary Fig. 9d), suggesting that TPL2 pathway does not directly influence SFTSV in 198 
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vitro replication. To test the role of NSs in SFTSV pathogenesis, we used two lethal challenge 199 
mouse models: Ifnar-/- mice and anti-IFNAR1-blocking antibody-treated WT mice or Tpl2-/- mice 200 
that were passively administered 2 mg of an anti-IFNAR1-blocking antibody or isotype control 201 
IgG antibody 1 day prior to infection. Upon SFTSV-WT infection, Ifnar-/- mice or anti-IFNAR1 202 
antibody-treated WT mice rapidly lost weight, showed severe symptoms, and died over a period 203 
of 4-5 days or 5-6 days p.i, respectively (Fig. 4a and 4g). Remarkably, 100% of anti-IFNAR1 204 
antibody-treated Tpl2-/- mice recovered from initial weight loss and survived SFTSV-WT 205 
infection (Fig. 4b). Control IgG-treated WT or Tpl2-/- mice did not show any symptom and weight 206 
loss, and survived SFTSV infection (Fig. 4ab). Furthermore, SFTSV-WT copy numbers were 207 
approximately 5 logs lower in spleens of anti-IFNAR1 antibody-treated Tpl2-/- mice at 4 days p.i 208 
than in those of anti-IFNAR1 antibody-treated WT mice (Supplementary Fig. 9e). Remarkably, 209 
the administration of TPL2 inhibitor (CAS871307-18-5) substantially improved the survival of 210 
anti-IFNAR1 antibody-treated wild-type mice infected with SFTSV: 80% of TPL2 inhibitor-treated 211 
mice (9/11) survived SFTSV infection (Fig. 4cd). These data suggest that the NSs-mediated 212 
activation of the TPL2 signalling pathway is required for the SFTSV-induced lethal phenotype, 213 
and that the inhibition of TPL2 signalling pathway is a potent therapeutic approach to treat 214 
SFTSV pathogenesis. 215 
 To further investigate role of the NSs-mediated IL-10 production in viral pathogenesis, 216 
anti-IFNAR1 antibody-treated Il-10-/- mice were infected with SFTSV-WT. Compared to WT mice 217 
that succumbed to infection, 70% of Il-10-/- mice (5/7) recovered from weight loss and survived 218 
SFTSV-WT infection (Fig. 4ef). Moreover, Ifnar-/- mice were infected with SFTSV-WT or SFTSV-219 
PA. By striking contrast to SFTSV-WT-infected Ifnar-/- mice that died over a period of 4-5 days 220 
p.i, 70% of SFTSV-PA-infected Ifnar-/- mice showed minor symptoms, recovered from weight 221 
loss and survived, whereas 30% of them showed moderate symptoms and died over a period of 222 
8-15 days p.i (Fig. 4gh). Remarkably, the administration of recombinant mouse IL-10 (rmIL-10) 223 
to SFTSV-PA-infected Ifnar-/- mice promptly led to severe symptoms, rapid weight loss, and 224 
death at 5-8 days p.i (Fig. 4gh, yellow triangle). The rmIL-10 treatment of mock-infected Ifnar-/- 225 
mice did not lead to any symptoms or death. Finally, compared to SFTSV-WT-infected mice, 226 
SFTSV-KR-infected mice showed no symptom and weight loss, and ultimately survived (Fig. 4 227 
ij). In summary, NSs-WT binds ABIN2 and induces TPL2-mediated IL-10 production; NSs-PA 228 
strongly binds ABIN2 but cannot induce TPL2-mediated IL-10 production; and NSs-KR neither 229 
binds ABIN2 nor induces TPL2-mediated IL-10 production (Supplementary Table 2). Correlated 230 
with TPL2 activation and IL-10 production, SFTSV-WT induces pathogenesis but SFTSV-KR 231 
and SFTSV-PA do not induce pathogenesis. Thus, NSs-WT binds ABIN2 to enhance TPL2-232 
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ABIN2-p105 signalling activity to induce IL-10 production for viral pathogenesis. 233 
 As seen in SFTSV-infected patients (Fig. 1o), IL-10 levels were increased in the acute 234 
phase of SFTS patients and further induced to higher levels in fatal cases12,26. This suggests 235 
that upon SFTSV infection, NSs targets TPL2 signalling pathway to produce IL-10 cytokine that 236 
creates a local immune suppressive environment to allow high viral replication, ultimately 237 
leading to viral pathogenesis. Thus, the SFTSV NSs and the host’s TPL2 signalling pathway are 238 
potential therapeutic targets to treat SFTSV-infected patients. 239 
240 
 9
Methods 241 
 242 
Bacterial strains, mammalian cell lines, and culturing conditions 243 
E. coli Top10 and DH10B were grown in LB (Lenox, Sigma) medium for genetic manipulations 244 
with appropriate antibiotics (Ampicillin 50 µg/ml, Kanamycin 50 µg/ml). HEK293T, HeLa, and 245 
mouse macrophage Raw264.7 cells were cultured in Dulbecco's modified Eagle's medium 246 
(DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Seradigm) and 100 U/ml 247 
penicillin, and 100 μg/ml streptomycin (1% Pen/Strep, Gibco). All cells were maintained at 37°C 248 
with 5% CO2. SFTSV NSs-WT, NSs-PA and NSs-KR stably expressing Raw264.7 cells were 249 
generated by transfection with pIRES-NSs-3xFlag-puro, followed by selection with puromycin 250 
(0.5 μg/ml, Gibco). For viral infection study, Heartland virus, MO-4 (NR-49771) was obtained 251 
through BEI Resources, NIAID, NIH, as part of the WRCEVA program and Uukuniemi virus was 252 
kindly provided from a collaborator.  253 
 254 
Preparation of bone marrow-derived macrophages (BMDMs) 255 
Bone marrow cells (BMs) were removed from femur and tibia, and red blood cells were lysed. 256 
For differentiation into BMDMs, BMs were suspended in DMEM supplemented with 20% MCSF 257 
containing L929 supernatants, 10% FBS (Seradigm) and 1% Pen/Strep (Gibco) and plated in a 258 
10 cm non-treated plate (1.5x107 cells/plate). On Day 3 or 4, the fresh media containing 10% 259 
MCSF was added. After 7 days, BMDMs were used for experiment (3x105 cells/well of a 24-well 260 
culture plate).  261 
 262 
Plasmids and reagents 263 
DNA encoding NSs from SFTS, Heartland, Bhanja, Granada or Lone Star phleboviruses were 264 
synthesized by Integrated DNA Technologies (IDT). cDNAs for human ABIN1, 2, 3, TPL2, and 265 
NFκB1/p105 were obtained from Addgene and Origene. All constructs for transient and stable 266 
expression in mammalian cells include pEF-MCS-IRES-puro, pEBG-GST-MCS, pCDH-CMV-267 
MCS-EF1-puro (System Biosciences, Dual promoter) vectors. All NSs-expression plasmids 268 
contain a C-terminal 3xFlag epitope tag, ABIN1/2/3-expression plasmids have a C-terminal V5 269 
epitope tag, TPL2-expression plasmids have N-terminal Myc epitope tag or C-terminal GFP tag 270 
for SiMPull assay, and the p105-expression plasmid contains a C-terminal mCherry tag for 271 
SiMPull assay. Substitution and deletion mutants were constructed by a standard PCR cloning 272 
strategy. For the generation of recombinant viruses, five plasmids were transfected to BHK21-273 
T7 cells. pTVT7-ppL, pTVT7-ppM, and pTVT7-S encode three viral antigenomic segments 274 
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under T7 promoter and pTM1-ppL and pTM1-N produce RdRp and N protein, respectively, to 275 
support viral replication. For MAPKs inhibition, TPL2 kinase inhibitors (616404, Calbiochem and 276 
sc-204351, Santa Cruz), MEK kinase inhibitor (U0126, Calbiochem), and c-Raf1 kinase inhibitor 277 
(475958, Calbiochem) were used along with DMSO as a control. 278 
 279 
Mouse infection 280 
The USC Institutional Animal Care and Use Committee (IACUC) approved all animal studies. 281 
Tpl2-/- mice (C57BL/6 background) and PD-L1-/- mice (BALB/c background) were bred as 282 
littermate controls. C57BL/6 wild-type, BALB/c wild-type, Ifnar-/- mice (A129, C57BL/6 283 
background), Il-10-/- mice (C57BL/6 background) were purchased from the Jackson Laboratory. 284 
All mice were maintained in pathogen-free barrier at the USC animal facilities and were 285 
transferred into the BSL3 facility immediately prior to, and for the duration of the infection study. 286 
Mice were 8-12-weeks old during the course of the experiments and were age- and sex-287 
matched in each experiment. Sample size was based on empirical data from pilot experiments 288 
and publications. No additional randomization or blinding was used to allocate experimental 289 
groups. Immediately prior to infection, frozen SFTSV stock was thawed and centrifuged. Mice 290 
were intramuscularly infected with 105 PFU or 102 PFU of SFTSV per mouse in 150 μl total 291 
volume of inoculum. For disease reconstitution, a recombinant mouse IL-10 (BioLegend at 1 292 
μg/mouse) was injected intraperitoneally three times daily. To block the IFN signalling, anti-293 
mouse IFNAR1 IgG (MAR1-5A3, BioXcell at 2 μg/mouse) and its isotype IgG (MOPC-21, 294 
BioXcell at 2 μg/mouse) were injected intraperitoneally 1 day prior to virus infection. TPL2 295 
inhibitor CAS871307-18-5 (naphthyridine ATP-competitive inhibitor) was dissolved in DMSO 296 
and sesame oil (S3547, Sigma) was used as a vehicle to inject mice. To neutralize the PD-L1 297 
signalling, anti-mouse PD-L1 IgG (B7-H1, 10F.9G2, BioXcell) and its isotype IgG (LTF-2, 298 
BioXcell) were injected intraperitoneally 1 day after to virus infection. For the survival 299 
experiment, mice were weighed daily after infection. Spleen and liver tissues were collected and 300 
used for quantitative PCR.  301 
 302 
Co-immunoprecipitation (Co-IP) and GST pull-down (GST-PD)  303 
HEK293T or Raw264.7 cells were transfected with indicated DNA plasmids using standard 304 
polyethylenimine (PEI) or ViromerR RED, respectively. For SFTSV-NSs-GFP infection, NSs-305 
GFP-FUSE virus27 was kindly provided by a collaborator. Raw264.7 cells were infected by 306 
SFTSV-NSs-GFP for 24 h. Cells were collected at 48 h post-transfection followed by PBS 307 
washing and cell pellets were re-suspended in 1% NP-40 lysis buffer containing 50mM Tris-HCl 308 
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(pH 8.0), 150mM NaCl, 1% Nonidet P-40 (Sigma) supplemented with complete protease 309 
inhibitor EDTA-free cocktail (Roche). After sonication or freeze/thaw three times, whole-cell 310 
extracts (WCEs) were pre-cleared with Sepharose beads rotating at 4°C for 2 h, followed by 311 
filtering through a 0.45 μm polyethersulfone (PES) filter (Thermo Fisher). For Co-IP, pre-cleared 312 
WCEs were incubated with indicated antibodies at 4°C for 3-12 h, followed by further incubation 313 
with protein A/G agarose beads (Thermo Fisher) at 4°C for 3 h. For GST-PD, pre-cleared WCEs 314 
were incubated with glutathione S transferase (GSH)-conjugated Sepharose beads (GE) at 4°C 315 
for 2 h. Immobilized immune complexes or GST complexes containing beads were extensively 316 
washed five times using lysis buffer containing 1% NP40 buffer with various concentrations of 317 
NaCl (150-500 mM). Beads were eluted in 2X Laemmli dye and  heated for 5 min at 95°C and 318 
then subjected immunoblotting analysis.  319 
 320 
Immunoblotting analysis 321 
Whole-cell lysates (WCLs) were lysed in 1% NP40 buffer and measured for protein 322 
concentration by Bradford protein assay (Thermo Fisher) to equalize protein loading. Proteins 323 
were resolved on SDS-PAGE gels and transferred to PVDF membrane by semi-dry transfer at 324 
25 V for 30 min (Trans-Blot Turbo, Bio-Rad). All membranes were blocked in 5% milk in Tris 325 
buffered saline with Tween20 (TBST, pH 8.0, Sigma) and probed with indicated antibodies in 326 
5% milk or 5% BSA in TBST. Primary antibodies included: ABIN2 (H-300; Santa Cruz), TPL2 327 
(Cot, M-20; Santa Cruz), NF-κB1 (p105/p50, D4P4D; Cell Signaling), NF-κB (p65, D14E12; Cell 328 
Signaling), ERK1/2 (p44/42; Cell Signaling), Phospho-ERK1/2 (Phospho-p44/42, E10; Cell 329 
Signaling), MEK1/2 (9122, Cell Signaling), Phospho-MEK1/2 (Ser217/221; Cell Signaling), JNK 330 
(SAPK, Cell Signaling). Phospho-JNK (Phospho-SAPK, Thr183/Tyr185; Cell Signaling), p38 331 
(Cell Signaling), Phospho-p38 (Thr180/Tyr182; Cell signaling), IKKβ (L570; Cell Signaling), 332 
Phospho-IKKα/β (Ser176/180, 16A6; Cell Signaling), GFP (B-2; Santa Cruz), GST (B-14; Santa 333 
Cruz), β-actin (C4; Santa Cruz), Flag (rabbit-Flag; F7425; Sigma, mouse-Flag; F1804, Sigma), 334 
HA (rabbit-HA; PRB-101P; Covance, mouse-HA; 16B12; BioLegend), V5 (rabbit-V5; A190; 335 
Bethyl, mouse-V5; Invitrogen), Myc (rabbit-Myc; Poly9063; BioLegend, mouse-Myc; 9E10; 336 
BioLegend). For detection of viral proteins NSs and Gn, rabbit anti-SFTSV-NSs Ab14 and mouse 337 
anti-SFSTV-Gn Ab28 were kindly provided from collaborators. Appropriate horseradish 338 
peroxidase (HRP)-conjugated secondary antibodies were incubated on membranes in 5% milk 339 
in TBST at room temperature for 1 h and bands were developed with enhanced 340 
chemiluminescence (ECL) reagent (Thermo Fisher) and imaged on an LAS-4000 imager (Fuji) 341 
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or a ChemiDoc Touch (Bio-Rad). All source gels with uncropped blots are available in 342 
Supplementary information.  343 
 344 
Yeast two-hybrid assay 345 
Yeast two-hybrid assay was performed using the Matchmaker GAL4 Two-Hybrid System 3 346 
(Clontech Laboratories, Inc.) per manufacturer's instructions. SFTSV NSs (2-293 amino acids, 347 
aa) was subcloned into the vector pGBKT7 as bait. Saccharomyces cerevisiae AH109 cells 348 
expressing NSs were transformed with a human leukocyte matchmaker complementary DNA 349 
library. To test the interactions between proteins, the transformants were grown onto low-350 
stringency (lacking leucine and tryptophan) and high-stringency (lacking adenine, histidine, 351 
leucine and tryptophan) selection plates.  352 
 353 
Luciferase reporter assay 354 
HEK293T cells were seeded in 12-well plates at 4x105 cells per well in the growth medium and 355 
cultured overnight. To measure IFN-β, HEK293T cells were co-transfected with 100 ng of IFN-β 356 
luciferase reporter plasmid, 20 ng of TK-renilla luciferase plasmid and 100 ng of plasmid 357 
encoding NSs proteins. 48 h after transfection, WCLs were prepared and subjected to the Dual-358 
Glo luciferase assay per manufacturer’s instructions (Promega). Results are presented with 359 
renilla luciferase levels normalized by the firefly luciferase levels. Luciferase report assay was 360 
performed in triplicate with at least three independently transfected cell populations. 361 
 362 
Immunofluorescence confocal microscopy 363 
HeLa cells and Raw264.7 stable cells were seeded onto glass coverslips. After 24 h, cells were 364 
transfected using Lipofectamine 2000 (Invitrogen). Cells were washed 18 h after transfection, 365 
fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and blocked with 5% BSA 366 
for 1 h. Cells were stained with the designated primary antibodies, followed by labeling with anti-367 
mouse Alexa Fluor 568 or 488 and anti-rabbit Alexa Fluor 568 or 488 (Molecular Probes). After 368 
antibody labeling, cells were counterstained with Hoechst (33342, Molecular Probes). Cells 369 
were imaged with a confocal microscope (Nikon) and were processed with NIS-elements 370 
confocal (Nikon). 371 
 372 
Quantitative RT-PCR (qRT-PCR) 373 
Total RNA was extracted using TRI reagent (Sigma) and digested with DNaseI (Sigma). 1 μg of 374 
total RNA was reverse-transcribed into cDNA using iScript cDNA synthesis kit (Bio-Rad). 375 
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Diluted cDNAs (1:5 or 1:10) were quantified using the iQ SYBR Green Supermix kit (Bio-Rad) 376 
per manufacturer’s instructions. DNase and RNase free water (Sigma W4502) and filter tips 377 
were used. CFX96 PCR machine (Bio-Rad) was used for qRT-PCR analysis with the following 378 
thermocycler conditions: 95°C for 3 min, (95°C for 10 sec, 59°C for 20 sec, 72°C for 20 sec) x 379 
40 cycles, 95°C for 10 sec, melt curve analysis with 65°C to 95°C, increment 0.5°C for 5 sec, 380 
plate read added. Threshold cycle (Ct) of each gene was normalized to internal reference gene 381 
(either β-actin or GAPDH); ∆Ct = Ct, target gene – Ct, reference gene. Gene expression results are 382 
presented as relative mRNA level or fold change. Relative mRNA levels are calculated using the 383 
2−(∆Ct) method. Fold changes are calculated using the 2−(∆∆Ct) method; where the target gene 384 
relative to the control gene is determined by; ∆∆Ct = ∆Ct, target sample – ∆Ct, control sample. Gene-385 
specific probes (5’ to 3’) for qRT-PCR are mouse Il-10 (NM_010548, Forward-386 
CCCTGGGTGAGAAGCTGAAG and Reverse-CACTGCCTTGCTCTTATTTTCACA), mouse 387 
Ifnb1 (NM_010510, Forward- GCACTGGGTGGAATGAGACT and Reverse-388 
AGTGGAGAGCAGTTGAGGACA), mouse Actin (NM_007393, Forward-389 
TGAGAGGGAAATCGTGCGTGAC and Reverse-AAGAAGGAAGGCTGGAAAAGAG), human 390 
Il-10 (NM_000572, Forward-GGTTGCCAAGCCTTGTCTGA and Reverse-391 
AGGGAGTTCACATGCGCCT), and human Gapdh (NM_002046, Forward-392 
GAAGGTGAAGGTCGGAGTC and Reverse-GAAGATGGTGATGGGATTTC). 393 
 394 
Knockdown of gene expression 395 
Small interfering RNA (siRNA) targeting human ABIN2 (isoform accecssion numbers: 396 
NM_024309, NM_001161527, NM_001292016, purchased from Santa Cruz, sc-44638) was 397 
transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen). After 24 h incubation, 398 
Co-IP experiment was performed as described earlier. For control, siRNA-A (sc-37007, Santa 399 
Cruz) was included as a non-targeting 20-25 nt siRNA. Short hairpin RNA (shRNA) targeting 400 
mouse ABIN2 gene (5’-GCAGGAAGTTGAAAGACTTAC-3’) was introduced into Raw264.7 cells 401 
by lentivirus-mediated transduction. shRNA was cloned into pLKO.1 vector and lentivirus was 402 
produced by transfection of HEK293T cells with shRNA plasmid, packaging plasmid and 403 
envelope plasmid. Raw264.7 cells were spin-infected by lentivirus with polybrene (8 μg/ml) and 404 
were subjected to gene expression assay. 405 
 406 
Enzyme-linked immunosorbent assay 407 
Secreted cytokines in supernatants were quantified by VeriKine mouse IFN-β ELISA kit (PBL 408 
Biomedical Laboratories), OptEIA mouse IL-10 ELISA kit (BD Biosciences) per manufacturer’s 409 
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protocols. Raw264.7 cells were treated with LPS priming (20 ng/ml, 0111:B4 Sigma) or Sendai 410 
virus infection and the cell culture supernatants were collected at indicated time points. Control 411 
healthy participant sera and SFTSV-infected patient sera collected from Chungbuk National 412 
University College of Medicine and Korea National Research Institute of Health were subjected 413 
to Lumina Bio-Plex Multiplex Immunoassay to measure cytokines. 414 
 415 
Single-molecule pull-down (SiMPull) assay 416 
SiMPull technique combines the principles of a conventional pull-down assay with single-417 
molecule fluorescence microscopy and enables direct visualization of individual protein-protein 418 
interactions22. Protein-protein interaction and TPL2 complex formations were assessed using 419 
SiMPull assay. Briefly, HEK293T cells were transfected with the indicated DNA plasmids (NSs-420 
Flag, ABIN2-V5, TPL2-GFP and p105-mCherry) and lysates were applied to slides coated with 421 
biotinylated anti-V5 antibody (GTX77436, GeneTex) for ABIN2-V5 pull down. For binding, anti-422 
Flag-Cy3 antibody (Sigma) was used for detecting NSs-Flag. For complex formations, GFP and 423 
mCherry fluorescence were imaged for TPL2-GFP and p105-mCherry, respectively. Proteins 424 
immobilized on the slides were visualized by a TIRF microscope equipped with excitation laser 425 
488 nm (GFP) and 561 nm (mCherry or RFP). 20 different regions of the imaging surface were 426 
imaged and molecular numbers were quantified by IDL and MATLAB programs.  427 
 428 
Reverse genetics 429 
Recombinant viruses were generated as previously described14. Briefly, BHK21-T7 cells 430 
(1.5x105/ml) were transfected with 0.1 μg of pTM1-HB29ppL, 0.5 μg of pTM1-HB29N, and 1 μg 431 
of each pTVT7-based plasmid expressing cDNA copies of the viral antigenomic segments, 432 
using 3 μl of TransIT-LT1 (Mirus Bio LLC) per μg of DNA as transfection reagent. After 7 days, 433 
the virus-containing supernatants were collected, clarified by low-speed centrifugation, and 434 
stored at -80°C. Stocks of recombinant viruses were grown in Vero E6 cells (1.5x105/ml) at 435 
37°C by infecting at MOI=0.01 and harvesting culture medium at 7 days p.i. The genome 436 
segments of recovered viruses were amplified by RT-PCR (M-MLV Reverse Transcriptase, 437 
Promega), and their nucleotide sequences were determined to confirm the lack of mutations. 438 
pTVT7-S-NSs-PA and pTVT7-S-NSs-KR plasmids were constructed by using site-direct 439 
mutagenesis according to the manufacture’s protocol and subsequently used to make SFTSV-440 
PA or -KR viruses (GENEART Site-Directed Mutagenesis System, Invitrogen).  441 
 442 
Virus titration by plaque assay 443 
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Vero E6 cells were infected with serial dilutions of virus and incubated under an overlay 444 
consisting of DMEM supplemented with 2.5% FBS, 0.5% minimum essential amino acids, 0.5% 445 
sodium pyruvate, 0.5% Glutamax, 1% Pen/Strep and 1.2% Avicel (FMC BioPolymer) at 37°C for 446 
14 days. Cell monolayers were fixed with 10% formaldehyde in PBS. Following fixation, cell 447 
monolayers were stained with 1% Crystal Violet in 20% ethanol to visualize plaques.  448 
 449 
Viral copy number  450 
Viral loads of SFTSV-infected cells or tissues of infected mice were determined by qPCR. For M 451 
segment, forward primer was SFTS-M-F: 5’-AAGAAGTGGCTGTTCATCATTATTG-3’, reverse 452 
primer was SFTS-M-R: 5’-GCCTTAAGGACATTGGTGAGTA-3’ and the probe was SFTS-M-453 
Probe: 5’-6FAM-TCATCCTCCTTGGATATGCAGGCCTCA-TAM-3’ (synthesized by Sigma). 454 
qPCR cycling was performed using 10 ng of total RNA with SsoAdvancedTM Universal Probes 455 
Supermix (BioRad) per manufacturer’s instructions. The copy numbers were calculated as a 456 
ratio of the copy numbers to the standard control. 457 
 458 
Whole blood infection 459 
Peripheral blood specimens were obtained from healthy donors and stored temporarily at 37 °C 460 
in lithium heparin-containing tube (BD Biosciences) prior to infection. Blood specimens used in 461 
Fig. 1i were obtained from male and female subjects of equal distribution. SFTSV infections of 462 
whole blood were performed using MOI=1. Each infection mix consisted of 1 ml blood and 1 ml 463 
virus suspension prepared in serum-free DMEM. Samples were incubated at 37°C for 24 h with 464 
intermittent shaking. Mock infections using the cell-free fractions from Vero-E6 cultures were 465 
performed in parallel. All procedures performed in studies using human whole blood were in 466 
accordance with the ethical standards of the USC code of ethics. 467 
 468 
NanoString analysis 469 
Total RNA was isolated from Raw264.7 cells expressing NSs with or without LPS treatment and 470 
spleens of Ifnar-/- mice infected by SFTSV, and 100 ng was used to determine the absolute 471 
levels of gene expression through nCounter mouse immunology panel (~550 immune-related 472 
genes). Hybridization and nCounter were performed by the Molecular Genomics Core of USC, 473 
according to the manufacturer’s protocol (NanoString Technologies). In brief, reactions were 474 
hybridized for 20 h at 65°C, after which the products were used to run on the nCounter 475 
preparation station for removal of excess probes. Data were collected with the nCounter digital 476 
analyzer by counting individual barcodes. Data generated from the nCounter digital analyzer 477 
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were examined with the nSolver Analysis software 3.0 (NanoString Technologies). Data were 478 
normalized to the geometric means of spiked-in positive controls for assay efficiency and 479 
spiked-in negative controls to normalize for background. The data were further normalized to 480 
the housekeeping genes like Gapdh, Hprt and Tubb5, and reported as normalized RNA counts 481 
(means ± SEM). For further analysis, differential expression (DE) of genes in response to 482 
SFTSV-WT/SFTSV-PA infection versus Mock infection sample was performed and visualized as 483 
a volcano plot by using the Advanced Analysis module. In volcano plot, the -log10 P value of each 484 
gene is plotted (on the vertical axis) against its log2 fold-change (on the horizontal axis). For each gene, 485 
a single linear regression was fit using all selected covariates to predict expression. Output is 486 
shown with nonadjusted P value as well as Benjamini-Hochberg FDR. The genes of interest 487 
were both high in the graph (corresponding to a very small p-value) and at either the right or left 488 
side (corresponding to increased or decreased expression). 489 
 490 
Biosafety 491 
All work with infectious agents for SFTSV was done in the Wright Foundation and Hasting 492 
Foundation Laboratories Animal Biosafety Level 3 (BSL3/ABSL3) Facility at the Keck School of 493 
Medicine of USC. 494 
 495 
Statistical analysis 496 
All results are presented as mean ± SD. All experiments were repeated at least twice with a 497 
representative gel or plot being shown. Statistical analysis was performed using Prism 6.0 498 
(Graph Pad Software). The n values in the figure legend indicate the number of independent 499 
experiments and each experiment was conducted with two to three technical replicates. Where 500 
appropriate, column analyses were performed using an unpaired, two-tailed t-test with Welch's 501 
correction or one-way ANOVA with Bonferroni’s or Dunnett’s test was used for multi-component 502 
comparisons. For grouped analyses two-way ANOVA with Bonferroni’s or Dunnett’s test was 503 
performed. P values less than 0.05 (95% confidence interval) were considered significant. 504 
Comparison of mouse survival was estimated using Kaplan–Meier method and analyzed by log-505 
rank analysis. 506 
 507 
Data availability  508 
The data that support the findings of this study are available from the corresponding author 509 
upon request.   510 
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Figure 1. SFTSV NSs-mediated alteration of host gene expression. a, Inclusion body (IB) 620 
formation of NSs in Raw264.7 cells expressing Vector, NSs-WT, or NSs-PA was shown by 621 
confocal microscopy. NSs was detected by Alexa Fluor 568 (red) and nuclear DNA was stained 622 
with Hoechst (blue). Scale bars, 10 μm. This represents three independent expteriments. b, 623 
Expressions of IFN-β mRNA and protein in Raw264.7 cells expressing Vector, NSs-WT, or NSs-624 
PA (n=3 each) were measured by quantitative RT-PCR (qRT-PCR) and Enzyme-linked 625 
immunosorbent assay (ELISA) upon Sendai virus (SeV) stimulation for 12 h. c, d, Immune 626 
profiling in spleens. RNA from splenocytes of Ifnar-/- mice infected by SFTSV-WT (n=2) or 627 
SFTSV-PA (n=2) at 105 PFU/mice for 4 days was subjected to NanoString analysis. Differential 628 
gene expression in SFTSV-WT (c) and SFTSV-PA (d) infection compared to Mock (n=2) 629 
infection was presented as a volcano plot. e, Comparison of gene expression between 630 
macrophages expressing NSs-WT and spleens infected with SFTSV-WT in Venn diagram and 631 
Heat map. f, IL-10 mRNA in Raw264.7 cells (n=3) was measured by qRT-PCR. g, IL-10 ELISA 632 
in Raw264.7 cells at various time points (n=2 each) after LPS (20 ng/ml) treatment. h, IL-10 633 
mRNA in Raw264.7 cells (n=2) was measured by qRT-PCR after SeV infection for 9 h. i, IL-10 634 
ELISA in Raw264.7 cells (n=2) after SeV infection for 12 h. j-l, IL-10 mRNA levels were 635 
measured by qRT-PCR in Raw264.7 cells (n=2) (j), mouse bone marrow derived macrophages 636 
(BMDMs) (n=2) (k), and human whole blood (n=3) (l) after SFTSV-WT or SFTSV-PA infection 637 
(MOI 0.1) for 48 h. m, n, IL-10 mRNA expression was assessed by qRT-PCR in spleens (n=3) 638 
(m) and livers (n=3) (n) at 4 days after infection of 105 PFU of SFTSV-WT or SFTSV-PA. o, IL-639 
10 expression in healthy participant sera (n=5) and SFTSV-infected patient sera (n=32) was 640 
measured by Bio-Plex human cytokine assay. Data are represented as mean ± SD. P values for 641 
multiple t-test (two-tailed) in (g), one-way or two-way ANOVA using Bonferroni's multiple 642 
comparisons test in (b, f, h-n), and unpaired t-test (two-sided) with Welch’s correction in (o). 643 
Statistical information is described in Supplementary Table 3. 644 
 645 
Figure 2. NSs activates TPL2 ternary complex formation through the interaction with 646 
ABIN2. a, HEK293T cells were transfected by NSs-3xFlag and ABIN2-V5 and whole cell 647 
extracts (WCEs) were immunoprecipitated by anti-Flag antibody (Ab) or anti-V5 Ab, followed by 648 
immunoblotting with indicated Ab. b, Lysates of Raw264.7 cells expressing NSs-WT were used 649 
for immunoprecipitation with anti-Flag Ab, followed by immunoblotting with anti-ABIN2 Ab. c, 650 
Raw264.7 cells were infected with SFTSV-NSs-GFP for 24 h and immunoprecipitated by anti-651 
GFP Ab, followed by immunoblotting with anti-ABIN2 Ab. d, HEK293T cells were transfected by 652 
NSs-3xFlag, ABIN1-V5, ABIN2-V5 and ABIN3-V5 and immunoprecipitated by anti-V5 Ab, 653 
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followed by immunoblotting with anti-Flag Ab. e, Raw264.7 cells expressing Vector, NSs-WT, or 654 
NSs-PA were treated with LPS (1 μg/ml) for 0, 15, 30, and 60 min and cell lysates were 655 
immunoblotted for indicated proteins. f, HEK293T cells were transfected by p105-mCherry (P), 656 
TPL2-GFP (T), ABIN2-V5 (A), NSs-WT-3xFlag (NSs), or NSs-PA-3xFlag (PA) and cell lysates 657 
were applied to Single Molecular Pull-down (SiMPull) analysis. Six representative images were 658 
shown in upper panel and molecular numbers were counted in lower panel. Bar graph with 659 
average number of fluorophores per image. Error bars represent SD of the mean across >20 660 
images. This represents three independent experiments. Scale bars, 5 μm. g, HEK293T cells 661 
were transfected by NSs-3xFlag (WT, PA, and KR) and ABIN2-V5 and immunoprecipitated by 662 
anti-Flag Ab, followed by immunoblotting with anti-V5 Ab. h, IL-10 mRNA in Raw264.7 cells 663 
expressing NSs (WT, PA and KR, n=4) was measured by qRT-PCR. i, IL-10 mRNA expression 664 
was measured by qRT-PCR in spleens and livers (n=2 each) at 4 days after infection with 105 665 
PFU of SFTSV-WT and SFTSV-KR. Data are represented as mean ± SD. P values for two-way 666 
ANOVA using Bonferroni's multiple comparisons test in (h and i). Statistical information is 667 
described in Supplementary Table 3. Western blots in (a-e, g) are representative of three 668 
independent experiments. 669 
 670 
 671 
Figure 3. SFTSV NSs induces IL-10 expression by activating TPL2 signalling pathway. a, 672 
IL-10 ELISA of Raw264.7 cells expressing Vector, NSs-WT, or NSs-PA with DMSO (NT), TPL2 673 
inhibitor (INH, 5 μM), LPS (20 ng/ml), or LPS+TPL2 inhibitor (n=2 each) for 12 h. b, IL-10 ELISA 674 
of LPS (20 ng/ml) treated Raw264.7 cells (n=2) as described in (a) for 12 h with DMSO, TPL2 675 
inhibitor (5 μM), c-Raf inhibitor (10 μM), MEK inhibitor (U0126, 10 μM). c, IL-10 mRNA was 676 
measured by qRT-PCR in wild-type (WT) and Tpl2-/- BMDMs (n=4) infected with Vector, NSs-677 
WT, or NSs-PA lentivirus, followed by LPS (1 μg/ml) treatment for 6 h. d, IL-10 mRNA was 678 
measured by qRT-PCR in wild-type (WT), Tpl2-/- and Ifnar-/- BMDMs (n=2) upon SFTSV-WT or 679 
SFTSV-PA infection for 12, 24, and 48 h. e, Ifnar-/- BMDMs (n=2) were infected by mock and 680 
SFTSV-WT for 24 and 48 h with or without TPL2 inhibitor (INH, 10 μM), and IL-10 mRNA was 681 
then measured by qRT-PCR. f, IL-10 mRNA was measured by qRT-PCR in spleens of wild-type 682 
C57BL/6 and Tpl2-/- mice (n=4) pre-treated with anti-IFNAR1 or isotype IgG at 4 days p.i with 683 
mock, SFTSV-WT. g, h, Ifnar-/- BMDMs were infected by mock, SFTSV-WT and SFTSV-PA 684 
(n=2 each) for 24 and 48 h, and IL-10 mRNA levels were then assessed by qRT-PCR (g) and 685 
cell lysates were analyzed by immunoblotting for indicated proteins (h). i, Ifnar-/- BMDMs were 686 
infected by mock, SFTSV-WT and SFTSV-PA for 48 h with or without TPL2 inhibitor (INH, 10 687 
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μM), and cell lysates were immunoblotted for indicated proteins. Data are represented as mean 688 
± SD. P values for one-way or two-way ANOVA using Dunnett's multiple comparisons test in (a-689 
e, h) and unpaired t-test (two-sided) in (a, c, f). Statistical information is described in 690 
Supplementary Table 3. Western blots in (g, i) are representative of two independent 691 
experiments. 692 
 693 
 694 
Figure 4. NSs-mediated activation of TPL2 signalling pathway is required for SFTSV-695 
induced lethal phenotype. a, b, Wild-type C57BL/6 and Tpl2-/- mice were treated with anti-696 
IFNAR1 (n=7 for WT, n=10 for Tpl2-/-)or isotype IgG (n=3 for each) intraperitoneally 1 day prior 697 
to intramuscular infection with 105 PFU of SFTSV-WT. Mice were then monitored (a) and 698 
weighed (b) for 15 days. c, d, Wild-type C57BL/6 mice were treated with anti-IFNAR1 IgG or 699 
isotype IgG intraperitoneally 1 day prior to intramuscular infection with 105 PFU of SFTSV-WT. 700 
Subsequently, infected mice were treated with TPL2 inhibitor (INH, 10 mg/kg at day 1, 2, 3, p.i, 701 
n=3 for Isotype, n=11 for anti-IFNAR1) or DMSO (n=3 for each), and then monitored (c) and 702 
weighed (d) for 15 days. e, f, Wild-type C57BL/6 and Il-10-/- mice were treated with anti-IFNAR1 703 
IgG or isotype IgG intraperitoneally 1 day prior to intramuscular infection with 105 PFU of 704 
SFTSV-WT (n=7 for each). For infection control, three mice (n=3) were only treated with anti-705 
IFNAR1 IgG. Mice were then monitored (e) and weighed (f) for 15 days. g, h, Ifnar-/- mice were 706 
intramuscularly infected with 102 PFU of SFTSV-WT (n=10), SFTSV-PA (n=7) or SFTSV-PA 707 
together with recombinant mouse IL-10 (rmIL-10, 1 μg/mouse at day 1, 2, 3 p.i, n=7) 708 
intraperitoneally, and mice were monitored (g) and weighed (h) for 15 days. i, j, Wild-type 709 
C57BL/6 mice were treated with anti-IFNAR1 IgG or isotype IgG intraperitoneally 1 day prior to 710 
intramuscular infection with 105 PFU of SFTSV-WT (n=8) or SFTSV-KR (n=7) and then 711 
monitored (i) and weighed (j) for 15 days. The survival curves were estimated using Kaplan–712 
Meier method and analyzed by log-rank analysis with P values (two-sided). Statistical 713 
information is described in Supplementary Table 3. 714 
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